Research programme: tyrosine kinase inhibitors - Onconova

Drug Profile

Research programme: tyrosine kinase inhibitors - Onconova

Alternative Names: Bcr-Abl/JAK2 inhibitors - Onconova; HER1 inhibitors - Onconova; HER2 inhibitors - Onconova; HER2-inhibitors; ON 150030; ON01135; ON012380; ON01370; ON044580; ON045270; ON128030; ON128060

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Onconova Therapeutics
  • Class Benzene derivatives; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 08 Sep 2010 Preclinical development is ongoing in USA
  • 08 Sep 2010 Research programme: tyrosine kinase inhibitors - Onconova is available for licensing as of 08 Sep 2010. http://www.onconova.com/partneringopportunities.shtml
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top